24 reports of this reaction
2.1% of all MEXILETINE HYDROCHLORIDE reports
#5 most reported adverse reaction
POOR QUALITY SLEEP is the #5 most commonly reported adverse reaction for MEXILETINE HYDROCHLORIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 24 FDA adverse event reports linking MEXILETINE HYDROCHLORIDE to POOR QUALITY SLEEP. This represents approximately 2.1% of all 1,120 adverse event reports for this drug.
Patients taking MEXILETINE HYDROCHLORIDE who experience poor quality sleep should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
POOR QUALITY SLEEP is a less commonly reported adverse event for MEXILETINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to poor quality sleep, the following adverse reactions have been reported for MEXILETINE HYDROCHLORIDE:
The following drugs have also been linked to poor quality sleep in FDA adverse event reports:
POOR QUALITY SLEEP has been reported as an adverse event in 24 FDA reports for MEXILETINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
POOR QUALITY SLEEP accounts for approximately 2.1% of all adverse event reports for MEXILETINE HYDROCHLORIDE, making it a notable side effect.
If you experience poor quality sleep while taking MEXILETINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.